Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 50

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 50
---
ersana Therapeutics    |
| Structure Therapeutics | NGM Biopharmaceuticals  |
| Vaxcyte                | Scholar Rock            |
| Xenon Pharmaceuticals  |                         |

In conjunction with the recommendation from Aon, the compensation committee took into account publicly-available data for the group of peer companies (the “2024 Compensation Peer Group”) listed below along with industry specific survey data, where appropriate. Selection criteria for determining 2024 Compensation Peer Group, used to establish the competitive market for the NEOs, generally include:

| Market Capitalization | Market capitalization approximately between $400 million and $4.0 billion, when the peer group was approved in October 2023 by the compensation committee for 2024 compensation purposes.                                    |
| Sector and Stage      | U.S.-based, publicly-traded pre-commercial biopharma companies, with focus on companies predominantly in Phase III of clinical trials. Crinetics was considered a Phase III company at the time the peer group was approved. |

<div align='center'>35</div>

| Headcount           | Generally under 500 employees.                                                                                          |
| Geographic Location | Focus on companies in California or other biotech “hub” locations. Crinetics’ headquarters is in San Diego, California. |

For 2024, this peer group consisted of the following companies:

| Akero TherapeuticsArcus Biosciences Avidity BiosciencesCerevel TherapeuticsCymaBay TherapeuticsCytokineticsIDEAYA BiosciencesImmunoGenImmunovantKura OncologyMadrigal Pharmaceuticals Morphic |     | Pliant Therapeutics Protagonist Therapeutics  ProthenaReplimune GroupSpringWorks TherapeuticsStructure TherapeuticsSyndax PharmaceuticalsTravere TherapeuticsVaxcyteViking TherapeuticsXenon Pharmaceuticals |

Our compensation committee reviewed the foregoing comparable company data in connection with its determinations of the 2024 base salaries, target annual incentives and equity awards for our named executive officers. The compensation committee does not rely entirely on that data to determine named executive officer compensation. Instead, as described above and consistent with past practice, the compensation committee members relied on their judgment and experience in setting those compensation levels and making those awards. However, the compensation committee generally strives to set cash compensation and target cash compensation at approximately the 50th percentile of the peer company data for comparable positions and total annual equity award value between the 50th and 75th percentile, but variations on